// App-Quantinova.ai

OP0001 : BARICITINIB, TOFACITINIB, UPADACITINIB, FILGOTINIB, AND CYTOKINE SIGNALING IN HUMAN LEUKOCYTE SUBPOPULATIONS: AN UPDATED EX-VIVO COMPARISON

Researchers

Presenter

  • I. Mcinnes

Principal Investigators

  • G. Rocha

  • R. E. Higgs

  • D. Dairaghi

  • T. Wehrman

  • E. Wang

  • Z. Xin

  • J. Ross Terres

  • T. Rooney

  • P. C. Taylor

Medical Centers

  • University of Glasgow, Glasgow, United Kingdom

  • Eli Lilly and Company, Indianapolis, United States of America

  • Primity Bio Inc., Fremont, United States of America

  • Eli Lilly and Company, Dunderrow, Kinsale, County Cork, Ireland

  • University of Oxford, Oxford, United Kingdom

Locations

  • United Kingdom

  • United States

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Peripheral blood mononuclear cell

Drug/Treatment

  • ABT-494

  • Baricitinib

  • Tasocitinib

  • Filgotinib

  • BARI

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved